← Back to Clinical Trials
Recruiting NCT06792877

NCT06792877 Mindfulness for Cognition in Early-stage Alzheimer's Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06792877
Status Recruiting
Phase
Sponsor VA Boston Healthcare System
Condition Mild Cognitive Impairment (MCI)
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2025-01-23
Primary Completion 2027-01-01

Trial Parameters

Condition Mild Cognitive Impairment (MCI)
Sponsor VA Boston Healthcare System
Study Type INTERVENTIONAL
Phase N/A
Enrollment 100
Sex ALL
Min Age 50 Years
Max Age 100 Years
Start Date 2025-01-23
Completion 2027-01-01
Interventions
Mindfulness InterventionWaitlist then mindfulness

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this clinical trial is to learn if mindfulness meditation can improve outcomes in older adults with and without cognitive impairment. The main questions it aims to answer are: 1. How does mindfulness impact thinking and memory? 2. How does mindfulness influence brain function and structure? 3. How does mindfulness affect daily function and quality of life? Researchers will compare all outcomes to one other groups. In one group, individuals will participate in a mindfulness class intervention; in the other group, individuals will not engage in any active interventions immediately, but will be placed on a waitlist for the mindfulness intervention. Researchers will compare all outcomes between the groups groups to determine whether the mindfulness interventions leads to greater improvement compared to no intervention (waitlist group). Participants will: * Be randomly assigned to participate in the mindfulness intervention, or no immediate intervention (waitlist) * Complete paper-and-pencil cognitive testing, surveys, computerized tasks, and neuroimaging measures (EEG and MRI) before and after the intervention Outcomes will be assess at baseline, 2 months, 4 months and 6 months.

Eligibility Criteria

Inclusion Criteria: * Healthy older adults will show cognitive performance within 1.0 SD for age \& education adjusted norms on a neuropsychological test battery * Mild cognitive impairment (MCI) participants will show performance on delayed recall or one more or more other cognitive domains worse than 1.5 SD for age \& education adjusted norms, an MMSE score between 25-30, and a MoCA score between 20-30. Exclusion Criteria: * Participants without a computer, smart phone and internet access will be excluded * If they cannot understand the informed consent form or have moderate dementia. * Mood disorders (e.g., PTSD, depression, anxiety) or alcohol and drug use that either interferes with day-to-day life or required hospitalization within the past 5 years * Cerebrovascular disease * Any medical condition whose severity could significantly impair cognition (e.g., stroke, frontotermporal dementia, Parkinson's disease) are exclusionary

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology